Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review
Open Access
- 9 May 2025
- journal article
- review article
- Published by Wiley in European Journal of Haematology
- Vol. 115 (2) , 104-116
Abstract
Objectives: The objective of this systematic literature review (SLR) combined with expert clinical review was to identify and rank prognostic factors and effect measure modifiers (EMMs) systematically and comprehensively in patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who initiate treatment after ≥ 2 prior lines of therapy (LoTs; 3L+ R/R DLBCL). Methods: We performed an SLR of studies published between 2016 and 2021 and extracted study characteristics, prognostic factors, and EMMs. This was followed by clinical review and ranking of findings by subject matter experts using questionnaires, follow‐up interviews, and quantitative ranking. Results: Across 46 included studies, the SLR identified 36 prognostic factors significantly associated with ≥ 1 clinical outcome. Based on subject matter expert ranking of the SLR‐derived list, the five most important prognostic variables in descending order are: early chemo‐immunotherapy failure, Eastern Cooperative Oncology Group performance status, refractory to last LoT, number of prior LoTs, and double‐ or triple‐hit lymphoma. Conclusions: This SLR and expert clinical review is the first to provide a comprehensive assessment of prognostic factors for 3L+ R/R DLBCL. No statistically significant EMMs were identified. This robust multi‐method approach can assist in selecting prognostic variables for comparative analyses between real‐world studies and clinical trials.Keywords
This publication has 62 references indexed in Scilit:
- RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphomaAnnals of Hematology, 2023
- Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesClinical Lymphoma Myeloma and Leukemia, 2022
- Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experienceAnnals of Hematology, 2021
- [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell LymphomaClinical Lymphoma Myeloma and Leukemia, 2021
- Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphomaCancer Medicine, 2020
- R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell LymphomaTransplantation and Cellular Therapy, 2020
- Long‐term outcomes among 2‐year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b‐cell lymphomaCancer, 2017
- Long-Term Outcomes Among Two-Year Survivors of Autologous Hematopoietic Cell Transplant for Hodgkin and Diffuse Large B-Cell LymphomaTransplantation and Cellular Therapy, 2017
- Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell TransplantTransplantation and Cellular Therapy, 2016